Compare AENT & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AENT | CRDF |
|---|---|---|
| Founded | 1990 | 1999 |
| Country | United States | United States |
| Employees | 697 | N/A |
| Industry | Durable Goods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.4M | 130.7M |
| IPO Year | N/A | 2012 |
| Metric | AENT | CRDF |
|---|---|---|
| Price | $7.15 | $1.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $10.00 | $9.63 |
| AVG Volume (30 Days) | 68.4K | ★ 674.1K |
| Earning Date | 02-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $365,993.00 |
| Revenue This Year | $3.44 | N/A |
| Revenue Next Year | $1.64 | N/A |
| P/E Ratio | $11.23 | ★ N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $2.21 | $1.48 |
| 52 Week High | $8.80 | $4.56 |
| Indicator | AENT | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 54.85 | 44.22 |
| Support Level | $6.01 | $1.51 |
| Resistance Level | $7.42 | $2.05 |
| Average True Range (ATR) | 0.64 | 0.12 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 70.29 | 1.96 |
Alliance Entertainment Holding Corp is a distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world. The company has two divisions: Alliance Home Entertainment, which offers full-service support across production, marketing, and retail execution. and Alliance Authentic, which focuses on licensed collectibles and branded merchandise, including partnerships with Handmade by Robots, Master Replicas, and Weta Workshop.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.